Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute-Reference-Cited by-同舟云学术

Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute

Published:2015-11-09 Issue:3 Volume:108 Page:
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Zeidner Joshua F.,Karp Judith E.,Blackford Amanda L.,Foster Matthew C.,Dees E. Claire,Smith Gary,Ivy S. Percy,Harris Pamela

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/108/3/djv335/17315078/djv335.pdf

Reference21 articles.

1. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B;Blood,1981

2. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study;Blood,1982

3. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study;Blood,1987

4. Anthracycline dose intensification in acute myeloid leukemia;N Engl J Med,2009

5. Age and acute myeloid leukemia;Blood,2006

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Developments and Future Perspectives of Purine Derivatives as a Promising Scaffold in Drug Discovery;Current Topics in Medicinal Chemistry;2024-03

2. Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia;Pharmaceutics;2022-06-17

3. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute;Journal of Clinical Oncology;2022-06-10

4. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges;Blood Reviews;2019-07

5. Contrasts between mucormycosis and aspergillosis in oncohematological patients;Medical Mycology;2019-02-28